For the fiscal quarter ending June 30, 2026, Citius Pharmaceuticals is expected to report a consensus EPS of -$0.36 on revenue of $5.46 million, as the stock currently trades at $0.76—well below the average analyst price target of $4.50.
Investors are laser-focused on the commercial trajectory of LYMPHIR, the company's recently launched oncology treatment, which is the primary driver of the company's transition to a revenue-generating entity.
While institutional demand for LYMPHIR has shown triple-digit percentage growth in vial orders, the market remains wary of the company's limited cash runway, currently projected to last only through November 2026.
Additionally, shareholders are seeking a definitive update on the Mino-Lok regulatory submission, which has faced significant delays despite meeting its Phase 3 endpoints in 2024.